SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9478	Companies
185492	Keywords
117871	Articles
99349	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/30/2025 at 21:33, 5 months 4 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/30/2025 at 07:35, 5 months 5 days ago

Sanofi Releases Q2 2025 Aide Mémoire

Forward-looking Statements Investor Information Financial Modeling Aide Mémoire Sanofi Q2 2025
PRESS RELEASE

published on 06/30/2025 at 07:30, 5 months 5 days ago

Press release: Availability of the Q2 2025 Aide mémoire
Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare

Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF

published on 06/25/2025 at 07:05, 5 months 10 days ago

Riliprubart Granted Orphan Drug Designation in the United States

FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE

published on 06/25/2025 at 07:00, 5 months 10 days ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine

Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF

published on 06/23/2025 at 07:05, 5 months 12 days ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 5 months 12 days ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 5 months 15 days ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
PRESS RELEASE

published on 06/20/2025 at 07:00, 5 months 15 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
BRIEF

published on 06/17/2025 at 13:45, 5 months 18 days ago

Sanofi Successfully Prices €1.5 Billion Bond Issue

Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note

Accesswire

Published on 12/05/2025 at 16:00, 33 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 48 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 58 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 8 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 1 hour 33 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 16:25, 8 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 23 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 33 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 33 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 33 minutes ago

Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

Les Echos

Published on 12/05/2025 at 15:10, 1 hour 22 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 48 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 22 hours 33 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 48 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 49 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE